Healthcare Aug 13, 2021 10:29 PM (GMT+8) · EqualOcean
Changchun hi tech announced that Jinsai pharmaceutical, a subsidiary of the company, plans to introduce the right to license the patented technology of an interleukin-2 mutant of Shanghai gaipu Biotechnology Co., Ltd. ("Shanghai gaipu biotechnology").
Related companies: